Global Thrombolysis Market Research and Forecast 2018-2023
The thrombolysis market is expected to grow significantly during the forecast period (2018-2023). Thrombolysis is also known as thrombolytic therapy. It is a treatment used to dissolve clots in blood vessels. It improves blood flow and prevents damages of tissues and organs. It is used as an emergency treatment to dissolve clots which are the main cause of heart attack and ischemic strokes. The global thrombolysis market is influenced by the various factors which include growing incidence and prevalence of blood related diseases such as deep vein thrombosis, pulmonary embolism, strokes, and heart attack. There are favorable reimbursement policies that are driving the market. Increasing geriatric population and obesity is the main cause of clotting which lead to the growth of the market. Thrombolysis is considered as the emergency medical service to dissolve the blood clots from the arteries that feed the heart and the brain. This advantage of thrombolysis helps for the growth of the market
Rising awareness through promotional initiatives and campaigns across the globe, rising healthcare expenditure, technological advancement and excessive collaborations between market players create the future opportunity for the growth of the market. Although there are various factors which hinders the growth of the market such as side effects of the treatment, high cost of the medicines and treatment, and lack of healthcare infrastructure in low economic countries.
Considering the regional outlook, the market is divided into North America, Europe, Asia Pacific and Rest of the world. North America rules the market with the highest incidence of deep vein thrombosis. In addition, there are advanced technologies and developed healthcare infrastructure in the region that propels the growth in North America. Europe stands second in the race due to high rate of diagnosis and treatment, ability of introducing new innovation by investing in research and development, and presence of good healthcare facilities. APAC is anticipated to capture a significant market share in the coming years due to rising consciousness among people, developing technology and healthcare amenities and large number of patient pool.
There are various companies contributing to the global Thrombolysis market with their products and services. Some of them are Eumedica Pharmaceuticals, Genentech Inc., SEDICO Co., Taj Pharmaceuticals, ND Pharma, Angiocare, Straub medicals, Mochida Pharmaceuticals Co. Ltd., ivascular, Syner- Med Ltd., and Teleflex Incorporation. With the technological advancement these companies are coming with new innovation and techniques with improved products and services in order to provide best possible treatment.
Research methodology
The market study of thrombolysis market is incorporated by extensive primary and secondary research conducted by research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report country level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders and industry experts. Primary research brings the authenticity in our reports.
Secondary sources include:
Market segmentation:
Global thrombolysis market is segmented on the basis of regional outlook and following segments:
1. Global thrombolysis market Research and Analysis, By Drug Types
2. Global thrombolysis market Research and Analysis, By Application
3. Global thrombolysis market Research and Analysis, By End User
4. Global thrombolysis market Research and Analysis, By Region
THE REPORT COVERS:
Rising awareness through promotional initiatives and campaigns across the globe, rising healthcare expenditure, technological advancement and excessive collaborations between market players create the future opportunity for the growth of the market. Although there are various factors which hinders the growth of the market such as side effects of the treatment, high cost of the medicines and treatment, and lack of healthcare infrastructure in low economic countries.
Considering the regional outlook, the market is divided into North America, Europe, Asia Pacific and Rest of the world. North America rules the market with the highest incidence of deep vein thrombosis. In addition, there are advanced technologies and developed healthcare infrastructure in the region that propels the growth in North America. Europe stands second in the race due to high rate of diagnosis and treatment, ability of introducing new innovation by investing in research and development, and presence of good healthcare facilities. APAC is anticipated to capture a significant market share in the coming years due to rising consciousness among people, developing technology and healthcare amenities and large number of patient pool.
There are various companies contributing to the global Thrombolysis market with their products and services. Some of them are Eumedica Pharmaceuticals, Genentech Inc., SEDICO Co., Taj Pharmaceuticals, ND Pharma, Angiocare, Straub medicals, Mochida Pharmaceuticals Co. Ltd., ivascular, Syner- Med Ltd., and Teleflex Incorporation. With the technological advancement these companies are coming with new innovation and techniques with improved products and services in order to provide best possible treatment.
Research methodology
The market study of thrombolysis market is incorporated by extensive primary and secondary research conducted by research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report country level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders and industry experts. Primary research brings the authenticity in our reports.
Secondary sources include:
- Financial reports of companies involved in the market
- Authentic Public Databases such as Department of Health, Thrombosis UK, National Heart, Lung, and Blood Institute, Centers for Disease Control and Prevention and others.
- Whitepapers, research-papers, and news blogs
- Company websites and their product catalogue
Market segmentation:
Global thrombolysis market is segmented on the basis of regional outlook and following segments:
1. Global thrombolysis market Research and Analysis, By Drug Types
2. Global thrombolysis market Research and Analysis, By Application
3. Global thrombolysis market Research and Analysis, By End User
4. Global thrombolysis market Research and Analysis, By Region
THE REPORT COVERS:
- Comprehensive research methodology of global thrombolysis market.
- This report also includes detailed and extensive market overview with key analyst insights.
- Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
- Analysis of regional regulations and other government policies impacting the global thrombolysis market.
- Insights about market determinants which are stimulating the global thrombolysis market.
1. REPORT SUMMARY
1.1. RESEARCH METHODS AND TOOLS
1.2. MARKET BREAKDOWN
1.2.1. BY SEGMENTS
1.2.2. BY GEOGRAPHY
1.2.3. BY STAKEHOLDERS
2. MARKET OVERVIEW AND INSIGHTS
2.1. DEFINITION
2.2. ANALYST INSIGHTS &CURRENT MARKET TRENDS
2.2.1. KEY FINDINGS
2.2.2. RECOMMENDATION
2.2.3. CONCLUSION
2.3. REGULATIONS
2.3.1. UNITED STATES
2.3.2. EUROPEAN UNION
2.3.3. CHINA
2.3.4. INDIA
2.3.5. REST OF THE WORLD
3. MARKET DETERMINANT
3.1. MOTIVATORS
3.1.1. GROWING INCIDENCE AND PREVALENCE OF BLOOD RELATED DISEASES
3.1.2. FAVOURABLE REIMBURSEMENT POLICIES
3.1.3. INCREASING OBESITY COUPLED WITH GERIATRIC POPULATION
3.1.4. TECHNOLOGICAL ADVANCEMENT
3.2. RESTRAINTS
3.2.1. SIDE EFFECTS OF THE TREATMENT
3.2.2. LACK OF HEALTH INFRASTRUCTURE IN LOW ECONOMIC COUNTRIES
3.2.3. HIGH COST OF MEDICINES.
3.3. OPPORTUNITIES
3.3.1. PROMOTIONAL INITIATIVES AND CAMPAIGNS TO RAISE AWARENESS
3.3.2. INCREASING HEALTHCARE SPENDING
3.3.3. EXTENSIVE COLLABORATIONS BETWEEN MARKET PLAYERS
4. MARKET SEGMENTATION
4.1. BY DRUG TYPES
4.1.1. FIBRIN SPECIFIC DRUG
4.1.2. NON- FIBRIN SPECIFIC DRUG
4.2. BY APPLICATION
4.2.1. DEEP VEIN THROMBOSIS
4.2.2. ACUTE ISCHEMIC STROKES
4.2.3. PULMONARY EMBOLISM
4.2.4. ACUTE MYOCARDIAL
4.2.5. BLOCKED CATHETERS
4.3. BY END USER
4.3.1. HOSPITALS
4.3.2. AMBULATORY SURGICAL CENTRES
5. COMPETITIVE LANDSCAPE
5.1. KEY MARKET STRATEGIES
5.2. KEY COMPANY ANALYSIS
6. REGIONAL ANALYSIS
6.1. NORTH AMERICA
6.1.1. UNITED STATES
6.1.2. CANADA
6.1.3. REST OF NORTH AMERICA
6.2. EUROPE
6.2.1. UNITED KINGDOM
6.2.2. FRANCE
6.2.3. GERMANY
6.2.4. ITALY
6.2.5. SPAIN
6.2.6. REST OF EUROPE
6.3. ASIA PACIFIC
6.3.1. INDIA
6.3.2. CHINA
6.3.3. JAPAN
6.4. REST OF THE WORLD
7. COMPANY PROFILES
7.1. ANGIOCARE BV
7.2. ANGIODYNAMICS, INC.
7.3. ARGON MEDICAL DEVICES INC.
7.4. ATHERSYS, INC.
7.5. BAYER AG
7.6. BOEHRINGER INGELHEIM GMBH
7.7. BOSTON SCIENTIFIC CORPORATION
7.8. BRISTOL-MYERS SQUIBB
7.9. BTG PLC
7.10. EKOS CORPORATION
7.11. GENENTECH INC.
7.12. GLAXOSMITHKLINE PLC
7.13. IVASCULAR S.L.U
7.14. LEMAITRE VASCULAR, INC.
7.15. MEDTRONIC PLC
7.16. MICROBIX BIOSYSTEMS INC.
7.17. PENUMBRA INC
7.18. PORTOLA PHARMACEUTICALS, INC.
7.19. SOUTH EGYPT DRUG INDUSTRIES CO.
7.20. STRAUB MEDICAL AG
7.21. TELEFLEX INC.
7.22. TEVA PHARMACEUTICAL INDUSTRIES LTD.
1.1. RESEARCH METHODS AND TOOLS
1.2. MARKET BREAKDOWN
1.2.1. BY SEGMENTS
1.2.2. BY GEOGRAPHY
1.2.3. BY STAKEHOLDERS
2. MARKET OVERVIEW AND INSIGHTS
2.1. DEFINITION
2.2. ANALYST INSIGHTS &CURRENT MARKET TRENDS
2.2.1. KEY FINDINGS
2.2.2. RECOMMENDATION
2.2.3. CONCLUSION
2.3. REGULATIONS
2.3.1. UNITED STATES
2.3.2. EUROPEAN UNION
2.3.3. CHINA
2.3.4. INDIA
2.3.5. REST OF THE WORLD
3. MARKET DETERMINANT
3.1. MOTIVATORS
3.1.1. GROWING INCIDENCE AND PREVALENCE OF BLOOD RELATED DISEASES
3.1.2. FAVOURABLE REIMBURSEMENT POLICIES
3.1.3. INCREASING OBESITY COUPLED WITH GERIATRIC POPULATION
3.1.4. TECHNOLOGICAL ADVANCEMENT
3.2. RESTRAINTS
3.2.1. SIDE EFFECTS OF THE TREATMENT
3.2.2. LACK OF HEALTH INFRASTRUCTURE IN LOW ECONOMIC COUNTRIES
3.2.3. HIGH COST OF MEDICINES.
3.3. OPPORTUNITIES
3.3.1. PROMOTIONAL INITIATIVES AND CAMPAIGNS TO RAISE AWARENESS
3.3.2. INCREASING HEALTHCARE SPENDING
3.3.3. EXTENSIVE COLLABORATIONS BETWEEN MARKET PLAYERS
4. MARKET SEGMENTATION
4.1. BY DRUG TYPES
4.1.1. FIBRIN SPECIFIC DRUG
4.1.2. NON- FIBRIN SPECIFIC DRUG
4.2. BY APPLICATION
4.2.1. DEEP VEIN THROMBOSIS
4.2.2. ACUTE ISCHEMIC STROKES
4.2.3. PULMONARY EMBOLISM
4.2.4. ACUTE MYOCARDIAL
4.2.5. BLOCKED CATHETERS
4.3. BY END USER
4.3.1. HOSPITALS
4.3.2. AMBULATORY SURGICAL CENTRES
5. COMPETITIVE LANDSCAPE
5.1. KEY MARKET STRATEGIES
5.2. KEY COMPANY ANALYSIS
6. REGIONAL ANALYSIS
6.1. NORTH AMERICA
6.1.1. UNITED STATES
6.1.2. CANADA
6.1.3. REST OF NORTH AMERICA
6.2. EUROPE
6.2.1. UNITED KINGDOM
6.2.2. FRANCE
6.2.3. GERMANY
6.2.4. ITALY
6.2.5. SPAIN
6.2.6. REST OF EUROPE
6.3. ASIA PACIFIC
6.3.1. INDIA
6.3.2. CHINA
6.3.3. JAPAN
6.4. REST OF THE WORLD
7. COMPANY PROFILES
7.1. ANGIOCARE BV
7.2. ANGIODYNAMICS, INC.
7.3. ARGON MEDICAL DEVICES INC.
7.4. ATHERSYS, INC.
7.5. BAYER AG
7.6. BOEHRINGER INGELHEIM GMBH
7.7. BOSTON SCIENTIFIC CORPORATION
7.8. BRISTOL-MYERS SQUIBB
7.9. BTG PLC
7.10. EKOS CORPORATION
7.11. GENENTECH INC.
7.12. GLAXOSMITHKLINE PLC
7.13. IVASCULAR S.L.U
7.14. LEMAITRE VASCULAR, INC.
7.15. MEDTRONIC PLC
7.16. MICROBIX BIOSYSTEMS INC.
7.17. PENUMBRA INC
7.18. PORTOLA PHARMACEUTICALS, INC.
7.19. SOUTH EGYPT DRUG INDUSTRIES CO.
7.20. STRAUB MEDICAL AG
7.21. TELEFLEX INC.
7.22. TEVA PHARMACEUTICAL INDUSTRIES LTD.
LIST OF TABLES
Table 1 GLOBAL THROMBOLYSIS MARKET RESEARCH AND ANALYSIS BY DRUG TYPES, 2017-2023 ($ MILLION)
Table 2 GLOBAL FIBRIN SPECIFIC DRUG MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
Table 3 GLOBAL NON- FIBRIN SPECIFIC DRUG MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
Table 4 GLOBAL THROMBOLYSIS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2017-2023 ($ MILLION)
Table 5 GLOBAL DEEP VEIN THROMBOSIS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
Table 6 GLOBAL ACUTE ISCHEMIC STROKES MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
Table 7 GLOBAL PULMONARY EMBOLISM MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
Table 8 GLOBAL ACUTE MYOCARDIAL MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
Table 9 GLOBAL BLOCKED CATHETERS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
Table 10 GLOBAL THROMBOLYSIS MARKET RESEARCH AND ANALYSIS BY END USER, 2017-2023 ($ MILLION)
Table 11 HOSPITALS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
Table 12 GLOBAL AMBULATORY SURGICAL CENTRES MARKET RESEARCH AND ANALYSIS,2017-2023 ($ MILLION)
Table 13 NORTH AMERICAN THROMBOLYSIS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
Table 14 NORTH AMERICAN THROMBOLYSIS MARKET RESEARCH AND ANALYSIS BY DRUG TYPES, 2017-2023 ($ MILLION)
Table 15 NORTH AMERICAN THROMBOLYSIS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2017-2023 ($ MILLION)
Table 16 NORTH AMERICAN THROMBOLYSIS MARKET RESEARCH AND ANALYSIS BY END USER, 2017-2023 ($ MILLION)
Table 17 EUROPEAN THROMBOLYSIS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
Table 18 EUROPEAN THROMBOLYSIS MARKET RESEARCH AND ANALYSIS BY DRUG TYPES, 2017-2023 ($ MILLION)
Table 19 EUROPEAN THROMBOLYSIS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2017-2023 ($ MILLION)
Table 20 EUROPEAN THROMBOLYSIS MARKET RESEARCH AND ANALYSIS BY END USER, 2017-2023 ($ MILLION)
Table 21 ASIA PACIFIC THROMBOLYSIS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
Table 22 ASIA PACIFIC THROMBOLYSIS MARKET RESEARCH AND ANALYSIS BY DRUG TYPES, 2017-2023 ($ MILLION)
Table 23 ASIA PACIFIC THROMBOLYSIS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2017-2023 ($ MILLION)
Table 24 ASIA PACIFIC THROMBOLYSIS MARKET RESEARCH AND ANALYSIS BY END USER, 2017-2023 ($ MILLION)
Table 25 REST OF THE WORLD THROMBOLYSIS MARKET RESEARCH AND ANALYSIS BY DRUG TYPES, 2017-2023 ($ MILLION)
Table 26 REST OF THE WORLD THROMBOLYSIS MARKET RESEARCH AND ANALYSIS BY APPLICATIONS, 2017-2023 ($ MILLION)
Table 27 REST OF THE WORLD THROMBOLYSIS MARKET RESEARCH AND ANALYSIS BY END USER, 2017-2023 ($ MILLION)
Table 1 GLOBAL THROMBOLYSIS MARKET RESEARCH AND ANALYSIS BY DRUG TYPES, 2017-2023 ($ MILLION)
Table 2 GLOBAL FIBRIN SPECIFIC DRUG MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
Table 3 GLOBAL NON- FIBRIN SPECIFIC DRUG MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
Table 4 GLOBAL THROMBOLYSIS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2017-2023 ($ MILLION)
Table 5 GLOBAL DEEP VEIN THROMBOSIS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
Table 6 GLOBAL ACUTE ISCHEMIC STROKES MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
Table 7 GLOBAL PULMONARY EMBOLISM MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
Table 8 GLOBAL ACUTE MYOCARDIAL MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
Table 9 GLOBAL BLOCKED CATHETERS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
Table 10 GLOBAL THROMBOLYSIS MARKET RESEARCH AND ANALYSIS BY END USER, 2017-2023 ($ MILLION)
Table 11 HOSPITALS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
Table 12 GLOBAL AMBULATORY SURGICAL CENTRES MARKET RESEARCH AND ANALYSIS,2017-2023 ($ MILLION)
Table 13 NORTH AMERICAN THROMBOLYSIS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
Table 14 NORTH AMERICAN THROMBOLYSIS MARKET RESEARCH AND ANALYSIS BY DRUG TYPES, 2017-2023 ($ MILLION)
Table 15 NORTH AMERICAN THROMBOLYSIS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2017-2023 ($ MILLION)
Table 16 NORTH AMERICAN THROMBOLYSIS MARKET RESEARCH AND ANALYSIS BY END USER, 2017-2023 ($ MILLION)
Table 17 EUROPEAN THROMBOLYSIS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
Table 18 EUROPEAN THROMBOLYSIS MARKET RESEARCH AND ANALYSIS BY DRUG TYPES, 2017-2023 ($ MILLION)
Table 19 EUROPEAN THROMBOLYSIS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2017-2023 ($ MILLION)
Table 20 EUROPEAN THROMBOLYSIS MARKET RESEARCH AND ANALYSIS BY END USER, 2017-2023 ($ MILLION)
Table 21 ASIA PACIFIC THROMBOLYSIS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
Table 22 ASIA PACIFIC THROMBOLYSIS MARKET RESEARCH AND ANALYSIS BY DRUG TYPES, 2017-2023 ($ MILLION)
Table 23 ASIA PACIFIC THROMBOLYSIS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2017-2023 ($ MILLION)
Table 24 ASIA PACIFIC THROMBOLYSIS MARKET RESEARCH AND ANALYSIS BY END USER, 2017-2023 ($ MILLION)
Table 25 REST OF THE WORLD THROMBOLYSIS MARKET RESEARCH AND ANALYSIS BY DRUG TYPES, 2017-2023 ($ MILLION)
Table 26 REST OF THE WORLD THROMBOLYSIS MARKET RESEARCH AND ANALYSIS BY APPLICATIONS, 2017-2023 ($ MILLION)
Table 27 REST OF THE WORLD THROMBOLYSIS MARKET RESEARCH AND ANALYSIS BY END USER, 2017-2023 ($ MILLION)
LIST OF FIGURES
Figure 1 GLOBAL THROMBOLYSIS MARKET SHARE BY DRUG TYPES, 2017 VS 2023 (IN %)
Figure 2 GLOBAL THROMBOLYSIS MARKET SHARE BY APPLICATION, 2017 VS 2023 (IN %)
Figure 3 GLOBAL THROMBOLYSIS MARKET SHARE BY DISTRIBUTION CHANNEL, 2017 VS 2023 (IN %)
Figure 4 US THROMBOLYSIS MARKET SIZE, 2017-2023 ($MILLION)
Figure 5 CANADA THROMBOLYSIS MARKET SIZE, 2017-2023 ($MILLION)
Figure 6 UK THROMBOLYSIS MARKET SIZE, 2017-2023 ($MILLION)
Figure 7 FRANCE THROMBOLYSIS MARKET SIZE, 2017-2023 ($MILLION)
Figure 8 GERMANY THROMBOLYSIS MARKET SIZE, 2017-2023 ($MILLION)
Figure 9 ITALY THROMBOLYSIS MARKET SIZE, 2017-2023 ($MILLION)
Figure 10 SPAIN THROMBOLYSIS MARKET SIZE, 2017-2023 ($MILLION)
Figure 11 ROE THROMBOLYSIS MARKET SIZE, 2017-2023 ($MILLION)
Figure 12 INDIA THROMBOLYSIS MARKET SIZE, 2017-2023 ($MILLION)
Figure 13 CHINA THROMBOLYSIS MARKET SIZE, 2017-2023 ($MILLION)
Figure 14 JAPAN THROMBOLYSIS MARKET SIZE, 2017-2023 ($MILLION)
Figure 15 ROASIA PACIFIC THROMBOLYSIS MARKET SIZE, 2017-2023 ($MILLION)
Figure 16 REST OF THE WORLD THROMBOLYSIS MARKET SIZE, 2017-2023 ($MILLION)
Figure 1 GLOBAL THROMBOLYSIS MARKET SHARE BY DRUG TYPES, 2017 VS 2023 (IN %)
Figure 2 GLOBAL THROMBOLYSIS MARKET SHARE BY APPLICATION, 2017 VS 2023 (IN %)
Figure 3 GLOBAL THROMBOLYSIS MARKET SHARE BY DISTRIBUTION CHANNEL, 2017 VS 2023 (IN %)
Figure 4 US THROMBOLYSIS MARKET SIZE, 2017-2023 ($MILLION)
Figure 5 CANADA THROMBOLYSIS MARKET SIZE, 2017-2023 ($MILLION)
Figure 6 UK THROMBOLYSIS MARKET SIZE, 2017-2023 ($MILLION)
Figure 7 FRANCE THROMBOLYSIS MARKET SIZE, 2017-2023 ($MILLION)
Figure 8 GERMANY THROMBOLYSIS MARKET SIZE, 2017-2023 ($MILLION)
Figure 9 ITALY THROMBOLYSIS MARKET SIZE, 2017-2023 ($MILLION)
Figure 10 SPAIN THROMBOLYSIS MARKET SIZE, 2017-2023 ($MILLION)
Figure 11 ROE THROMBOLYSIS MARKET SIZE, 2017-2023 ($MILLION)
Figure 12 INDIA THROMBOLYSIS MARKET SIZE, 2017-2023 ($MILLION)
Figure 13 CHINA THROMBOLYSIS MARKET SIZE, 2017-2023 ($MILLION)
Figure 14 JAPAN THROMBOLYSIS MARKET SIZE, 2017-2023 ($MILLION)
Figure 15 ROASIA PACIFIC THROMBOLYSIS MARKET SIZE, 2017-2023 ($MILLION)
Figure 16 REST OF THE WORLD THROMBOLYSIS MARKET SIZE, 2017-2023 ($MILLION)
